Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

uch patients are characterized by presence of chromosomal abnormalities (i.e., deletions of chromosome 17p or 11q) or short remissions (less than 3 years) after standard chemo-immunotherapy. To develop an alternative therapy regimen for this patient population, researchers explored the combination of ibrutinib and the anti-CD20 antibody rituximab in high-risk CLL.

In this Phase II study conducted at The University of Texas MD Anderson Cancer Center in Houston, ibrutinib was given in combination with rituximab to evaluate its potential to accelerate and improve CLL patient responses. Forty patients were treated with 420 mg of ibrutinib daily in combination with weekly rituximab for four weeks, followed by ibrutinib daily plus monthly rituximab until month six, followed by single-agent ibrutinib.

Positive responses to therapy were shown among the vast majority of treated patients. At four months of follow-up, the overall response rate was 85 percent and almost all (38 of 40) patients continued on therapy without disease progression. Of the 20 patients evaluable for early response, 17 achieved a partial remission. Patient health questionnaires also noted improvements in health and the quality of life of all treated patients.

Overall, the regimen was well-tolerated among participants, with little severe toxicity that was largely unrelated and short in duration. After treatment with ibrutinib-rituximab (iR) combination therapy, most cases of early lymphocytosis (increase in white blood cells that is a sign of infection), due to the ibrutinib-induced shift of CLL cells from lymph node tissues into the blood, peaked early and resolved; at four months of follow-up, only three treated patients had lymphocytosis that had not yet resolved. This shorter lymphocytosis duration, when compared to single-agent use of ibrutinib, is presumably related to the addition of rituximab.

"We know that high-risk CLL patients struggle with the effects of
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... 2014 Buying a policy for different life ... unsure about available coverage types by insurers in the U.S. ... policy pricing to the public using its sortable tool at ... is free and is expected to promote the discounts and ... throughout the U.S. The system is designed to help an ...
(Date:8/22/2014)... The regional economy is about to get ... the grow again. The plant will invest $100 ... boost production of the popular Highlander midsize sport utility ... to $4 billion. This step allows Toyota to utilize ... to adjust its product mix to meet changing customer ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... 11 (BIM) deletion in advanced non-small cell lung ... survival (PFS) in epidermal growth factor receptor (EGFR) ... patients. Also, BIM deletion independently predicts overall survival ... protein can activate the programmed cell death also ... deletion has been detected in 12.8% of the ...
Breaking Medicine News(10 mins):Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2
... organization will leverage Risk MonitorPro, (R) ... patient feedback and adverse events,CAMBRIDGE, MA, ... of healthcare quality and safety software, announced today that ... patient safety and quality of care initiatives. , Named ...
... poised to enter Animal Health Rapid Diagnostics Market with ... Jan. 13 Abaxis, Inc. (Nasdaq: ABAX ... instruments for both the medical and veterinary markets, announced ... Scientific for the manufacturing of a Canine Heartworm Lateral ...
... Association (NEA) awarded its Seal of Acceptance to ... NEA Seal of Acceptance is part of the association,s ... to improve the quality of life for people who ... our criteria for having no irritating ingredients and being ...
... Insurance Reports Job Opportunities for Commissioned Insurance Sales Agents Across the ... ... 2009 -- Despite recent reports by the U.S. Bureau of Labor ... continue throughout 2009, Combined Insurance, a leading provider of supplemental ...
... device can be used in home, rather than hospital, and can ... ... (PRWEB) January 13, 2009 -- MedFaxx has announced ... combines the most used form of electrotherapy in the world clinically ...
... on its recent analysis of the autoimmune disease ... with the 2008 European Frost & Sullivan Excellence ... incorporation of synthetically modified peptides for the validation ... autoimmune diseases and is also looking to adopt ...
Cached Medicine News:Health News:Woman's Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 3Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Leading Insurer Reports Positive Outlook for U.S. Insurance Industry Jobs in 2009 2Health News:Leading Insurer Reports Positive Outlook for U.S. Insurance Industry Jobs in 2009 3Health News:North Carolina Company Announces First Chronic Pain Control Unit Combining Two Most Used Forms of Electrotherapy For Chronic Pain - Tens & Interferential 2Health News:North Carolina Company Announces First Chronic Pain Control Unit Combining Two Most Used Forms of Electrotherapy For Chronic Pain - Tens & Interferential 3Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 2Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 3Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 4
(Date:8/22/2014)... DUBLIN , August 22, 2014 /PRNewswire/ ... ) has announced the addition of the  ... to their offering.       (Logo: ... room with a sterile environment in a ... It is equipped with technically advanced equipment, ...
(Date:8/22/2014)... 2014 /CNW/ - On Aug. 20, at its annual ... Medical Association (CMA) voted on and approved a delegate ... medicinal cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed ... motion. The CMA is quite right to ... smoking any plant material, including medicinal cannabis. While some ...
(Date:8/22/2014)... 2014 Research and Markets has ... Intravenous Catheter Industry Report 2014" report to their ... Catheter Industry Report 2014 is a professional and in-depth ... catheter industry with a focus on the Chinese situation. ... industry including definitions, classifications, applications and industry chain structure. ...
Breaking Medicine Technology:Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global and Chinese Intravenous Catheter Industry Report 2014 2
... LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, ... focused on,the discovery and development of novel, ... of AV-412, a novel,next generation oral tyrosine ... mutant and drug-resistant lung cancer tumor,models. The ...
... Decreased Tumor Blood Vessel,Density and Serum PSA ... and TUSTIN, Calif., April 17, 2007,/PRNewswire-FirstCall/ -- ... company developing targeted,monoclonal antibodies for the treatment ... today announced that preclinical data,presented at the ...
Cached Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
ArcticTemp Upright Freezer -20C. Thick wall insulation keeps your samples colder. Reversible door with magnetic gaskets. 2 shelves and a wire basket. Heavy duty compressor with 5 year warranty....
Undercounter Freezer -25C. White. Front opening freezer. 4 cubic ft capacity. Reversible door. Three slide-out drawers. Extra thick CFC insulation. Front lock. Front indicator lights. Attractive tabl...
... F 250 is a portable system for ... temperature measurements. Temperature compensated pH results can ... probe (ATC) or a 3-in-1 electrode. • ... calibration with Auto-Find automatic buffer recognition for ...
... a highly accurate portable, waterproof system for pH, ... compensated pH results can be obtained when used ... electrode. • This GLP/GMP compliant system includes an ... a computer. Up to 100 data sets can ...
Medicine Products: